Status | Study |
Not yet recruiting |
Study Name: Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Condition: Autoimmune Bullous Dermatose Date: 2016-12-12 Interventions: Drug: Cellcept® in autoimmune bullous dermatoses The administration will follow the recommendations |
Available |
Study Name: Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Condition: Limbal Stem Cell Deficiency Stevens-johnson Syndrome Ocula Date: 2014-05-14 Interventions: Biological: cultivated oral mucosal epithelial sheet transplantation Autologous cultivated oral mucosal |
Withdrawn |
Study Name: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Condition: Stevens-Johnson Syndrome Toxic Epidermal Necrolysis (Lyell) Syndrome Date: 2014-04-27 Interventions: Drug: topical infliximab topical infliximab administered QID for 3 months followed by BID for 9 months |
Recruiting |
Study Name: Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Condition: Chemical Injuries Unspecified Complication of Corneal Transplant Date: 2012-04-10 Interventions: Drug: Riboflavin Used to treat donor cornea before implantation |
Available |
Study Name: The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells Condition: Alkaline Chemical Burn Of Cornea And Conjunctival Sac Acid Chemical Burn Of Cornea And Conju Date: 2011-04-21 Interventions: Procedure: collagenase Cultured limbal stem cells transplantation |
Completed |
Study Name: Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Condition: Ocular Cicatricial Pemphigoid Date: 2007-12-26 Interventions: Drug: Rituximab The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses ( |
Completed |
Study Name: Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Condition: Uveitis Cancer Infection Date: 2005-06-26 |